Drug
Sagopilone clinical trials
Also written ZK 219477 and ZK-EPO.
- studies test it
- 13
- open now
- 0
- in phase 3
- 0
- first study started
- 2005
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
13 studies that test it; most in 2006 (6)
| Year | Studies |
|---|---|
| 2005 | 3 |
| 2006 | 6 |
| 2007 | 3 |
| 2008 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 12
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 4
Bayer (9) · Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Nancy Lin, MD (1)
Studies
Open first, then newest update. How each study uses sagopilone is read from its arms, and is right about nine times in ten.
Testing it · 13
- ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian CancerCompletedPhase 2BayerNCT00325351Written as Sagopilone (ZK 219477) + carboplatin
- ZK-Epo Given With Prednisone in Patients With Metastatic Androgen-independent Prostate CancerCompletedPhase 2BayerNCT00350051Written as Sagopilone (ZK 219477) + prednisone
- Efficacy and Safety Study of ZK219477 in Patients With Recurrent Ovarian CancerCompletedPhase 2BayerNCT00246688Written as Sagopilone (BAY86-5302 , ZK219477)
- Safety and Efficacy Study of a New Chemotherapy Agent to Treat Small Cell Lung CancerTerminatedPhase 2BayerNCT00299390Written as Sagopilone (BAY86-5302, ZK 219477)
- Investigation of Mass Balance of the Test Drug and Major MetabolitesCompletedPhase 1BayerNCT00432302Written as Sagopilone (BAY 86-5302, ZK 219477)
- Evaluation of a New Agent for Treatment of Advanced Stage Breast CancerCompletedPhase 2BayerNCT00313248Written as Sagopilone (ZK 219477)
- Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-small-cell Lung CancerCompletedPhase 2BayerNCT00160069Written as Sagopilone (BAY86-5302, ZK 219477)
- Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Breast CancerCompletedPhase 2BayerNCT00288249Written as Sagopilone (BAY86-5302, ZK 219477)
- Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)CompletedPhase 2BayerNCT00751205Written as Sagopilone 16 mg/m^2 i.v., Acetyl-L-Carnitine (ALC) 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid
- Epothilone in Recurrent Glioblastoma PatientsCompletedPhase 2Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaNCT00397072Written as ZK 219477
- Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic MelanomaCompletedPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT00598507Written as ZK-EPO
- ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain MetastasesTerminatedPhase 2Nancy Lin, MDNCT00496379Written as ZK219477
- Epothilone ZK-219477 in Treating Patients With Recurrent GlioblastomaCompletedPhase 2European Organisation for Research and Treatment of Cancer - EORTCNCT00424060Written as sagopilone
Given in every arm · 1 — sagopilone is usual care beside what is tested
Codes
What other systems call sagopilone · ClinicalTrials.gg INT005298
- MeSH (NLM) C530494sagopiloneConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) KY72JU32FOSAGOPILONEConfirmed FDA, NLM, Wikidata
- Wikidata Q27282501sagopiloneConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C61072SagopiloneOne source FDA
- DrugBank DB12391One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C530494 | sagopilone | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | KY72JU32FO | SAGOPILONE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27282501 | sagopilone | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C61072 | Sagopilone | One source FDA |
| DrugBank | DB12391 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.